QL325 / Qilu Pharma - LARVOL DELTA

Preclinical development of QL325, a novel T cell engager targeting CLEC12A-positive AML (AACR 2024) - "In non-human primates, QL325 was tolerated up to 0.03 mg/kg for IV dosing and under 0.1 mg/kg for SC dosing, well above the predicted effective therapeutic dose. A phase 1 clinical trial is currently ongoing to determine the safety and early efficacy in patients with refractory or relapsed AML."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD34 • CLEC12A